Primary record
5-Heptenoic acid, 7-[3,5-dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-, [1.alpha.(Z),2.beta.(1E,3R*),3.alpha.,5.alpha.]-(.+-.)-
- 库存
- 5,236 克
- 纯度
- 98.7 %
- CAS
- 54276-17-4
化合物标识与属性
- CAS
- 54276-17-4
- PubChem CID
- 5311100
- SMILES
- C1[C@@H]([C@@H]([C@H]([C@@H]1O)/C=C/[C@H](COC2=CC=CC(=C2)C(F)(F)F)O)C/C=C\CCCC(=O)O)O
- Canonical SMILES
- O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)COc2cccc(C(F)(F)F)c2)[C@H](O)C[C@@H]1O
名称与同义词
- fluprostenol
- travoprost acid
- (+)-fluprostenol
- Fluprostenolum
- Fluoprostenol
- travoprost free acid
- Fluprostenol, (+)-
- 54276-17-4
- [3H](+)-fluprostenol
- (+/-)-Fluprostenol
- AC1NSJZQ
- Fluprostenol [INN:BAN]
- UNII-MEH3MCE8X1
- [3H]-Travoprost acid
- MEH3MCE8X1
- (A+/-)-Fluprostenol
- [3H]-(+)-fluprostenol
- Travoprost Related Compound A
- ICI 81,008
- Fluprostenolum [INN-Latin]
- RefChem:921725
- 358S7VUE5N
- FLUPROSTENOL [MI]
- UNII-358S7VUE5N
- FLUPROSTENOL [INN]
- CHEBI:60782
- D05TNX
- D08TWE
- fluprostenol monosodium salt
- ICI-80008 FREE ACID
- Fluprostenol Travoprost acid
- EINECS 255-029-3
- WWSWYXNVCBLWNZ-QIZQQNKQSA-N
- C23H29F3O6
- 40666-16-8
- ICI 80,008 FREE ACID
- Travoprost related compound A A
- BSPBio_001336
- DTXSID7046122
- SCHEMBL230607
- ICI 81008
- ICI-81008
- BML2-G08
- GTPL1940
- GTPL3417
- orb1306434
- CHEMBL1201379
- DTXCID5026122
- SCHEMBL29575183
- AL-5848
- Travoprost related compound A [USP]
- HMS1361C18
- HMS1791C18
- HMS1989C18
- HMS3402C18
- HMS3648H08
- EX-A3612
- FLUPROSTENOL,ETHANOL SOLUTION
- ZINC4474587
- Tox21_111778
- 1007AH
- 1771AH
- BDBM50206025
- MFCD03427566
- NCGC00160386-01
- Travoprost related compound A RS [USP]
- AKOS024458212
- C23-H29-F3-O6
- AL 5848
- CID5311100
- DB11519
- CID:5311100
- IDI1_033806
- NCGC00160386-02
- NCGC00160386-04
- NCGC00160386-05
- BT176360
- DA-68970
- FF103958
- MS-28380
- SID:53786902
- (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoic acid
- CAS-40666-16-8
- HY-108560
- J238.396I
- CS-0029169
- G90905
- TRAVOPROST RELATED COMPOUND A [USP-RS]
- 276F174
- C006326
- SR-01000946504
- 5-Heptenoic acid, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-buten-1-yl)cyclopentyl)-, (5Z)-
- A1032088
- SR-01000946504-1
- TRAVOPROST RELATED COMPOUND A [USP IMPURITY]
- BRD-K31611373-001-02-7
- Q27077691
- (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoic acid
- B1370-447705
- (5Z ,13E )-(9S,11R,15R )-9,11,15-Trihydroxy-16-(m-trifluoromethylphenoxy)-17,18,19,20-tetranor-5,13-prostadienoic acid
- (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-5-heptenoic Acid
- 16-(m-Trifluoromethylphenoxy)-17,18,19,20-tetranorprostaglandin F2alpha
- (+/-)-16-(3-Trifluoromethylphenoxy)tetranorprostaglandin F2alpha
- (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]cyclopentyl]hept-5-enoic acid
- 16-(m-Trifluoromethylphenoxy)-17,18,19,20-tetranorprostaglandin F2|A
- fluprostenol, ((1alpha(Z),2beta(1E,3R*),3alpha,5alpha)-(+-))-isomer
- rac-(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoic acid
- 16-(M-TRIFLUOROMETHYLPHENOXY)-17,18,19,20-TETRANORPROSTAGLANDIN F2.ALPHA.
- fluprostenol, ((1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-(+-))-isomer
- (+/-)-(Z)-7-((1R*,2R*,3R*,5S*)-3,5-DIHYDROXY-2-((E)-(3R*)-3-HYDROXY-4-((.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-M-TOLYL)OXY)-1-BUTENYL)CYCLOPENTYL)-5-HEPTENOATE
- (5Z)-7-((1R,2R,3R,5S)-2-((R,E)-4-(3-(trifluoromethyl)phenoxy)-3-hydroxybut-1-enyl)-3,5-dihydroxycyclopentyl)hept-5-enoic acid
- (5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]cyclopentyl]-5-heptenoic acid
- (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoic acid
- (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoic acid
- (Z)-7-[(1alpha)-3alpha,5alpha-Dihydroxy-2beta-[(3R,1E)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-5-heptenoic acid
- (Z)-7-[(1alpha,2beta,3alpha,5alpha)-3,5-Dihydroxy-2-[(3R,1E)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-5-heptenoic acid
- [1R-[1|A(Z),2|A(1E,3R*),3|A,5|A]]-7-[3,5-Dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-5-heptenoic Acid
- [1R-[1alpha(Z),2beta(1E,3R*),3alpha,5alpha]]-7-[3,5-Dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-5-heptenoic Acid
- 255-029-3
- 5-HEPTENOIC ACID, 7-((1R,2R,3R,5S)-3,5-DIHYDROXY-2-((1E,3R)-3-HYDROXY-4-(3-(TRIFLUOROMETHYL)PHENOXY)-1-BUTEN-1-YL)CYCLOPENTYL)-, (5Z)-REL-
- 5-HEPTENOIC ACID, 7-(3,5-DIHYDROXY-2-(3-HYDROXY-4-(3-(TRIFLUOROMETHYL)PHENOXY)-1-BUTENYL)CYCLOPENTYL)-(1.ALPHA.(Z),2.BETA.(1E,3R*),3.ALPHA.,5.ALPHA.)-,(+/-)-
- 5-HEPTENOIC ACID, 7-(3,5-DIHYDROXY-2-(3-HYDROXY-4-(3-(TRIFLUOROMETHYL)PHENOXY)-1-BUTENYL)CYCLOPENTYL)-, (1.ALPHA.(Z),2.BETA.(1E,3R*),3.ALPHA.,5.ALPHA.)-
- 5-Heptenoic acid, 7-[3,5-dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-, [1.alpha.(Z),2.beta.(1E,3R*),3.alpha.,5.alpha.]-(.+-.)-
- 5-Heptenoic acid, 7-[3,5-dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-, [1.alpha.(Z),2.beta.(1E,3R*),3.alpha.,5.alpha.]-(.+.)-
- rac-(5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoic acid